Revvity Inc. Stock - background snapshot on diagnostics and life science tools
Published on 06/21/2026 at 10:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edited by ad hoc news Background & Management Desk. Verified prior to publication on 06/21/2026, 08:08 UTC. Details in the imprint.
Revvity Inc. (US76155R1086) is currently in a quiet period without newly dated market-moving headlines in the past 24 hours. Against this backdrop, this Sunday update focuses on the company’s background, management setup and business profile for retail investors.
Background and price data on Revvity stock
All recent reports, filings and market data on Revvity are bundled on the dedicated topic page and the company’s investor-relations site.
How Revvity came together
Revvity emerged in 2023 as the rebranded life science and diagnostics business that was previously part of PerkinElmer, following a separation of the analytical instruments segment and an earlier sale of the applied, food and enterprise services units.
The company positions itself as a science and technology player focused on translational multi-omics, biomarker discovery, diagnostics and advanced imaging solutions for pharma, biotech and clinical labs, according to its corporate profile.
Leadership and corporate structure
Revvity is led by President and CEO Prahlad Singh, who previously served as chief executive of PerkinElmer and continued after the rebranding, while the board oversees capital allocation, portfolio strategy and risk management, per company governance disclosures.
The group is headquartered in Waltham, Massachusetts, and reports results in two main operating segments, Diagnostics and Life Sciences, which together serve customers in more than 190 countries through a mix of direct sales and distributors.
What the company sells
Revvity generates revenue from prenatal and neonatal screening assays, reagents, instruments and software, as well as genomic and proteomic research tools, imaging platforms and automation solutions used by pharmaceutical and biotech customers in drug discovery and development workflows.
Where the stock trades today
The shares of Revvity Inc. (US76155R1086) trade on the New York Stock Exchange in US dollars; the latest verifiable quote and market capitalization are available on major financial data platforms and the company’s investor-relations site.
Key facts on Revvity stock
- Company: Revvity Inc.
- ISIN: US76155R1086
- Ticker: RVTY
- Venue: NYSE
- Sector / Industry: Health Care - Life Sciences Tools & Services
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
